MIM
AMRX icon

Macroview Investment Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Macroview Investment Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1
Closed -$5 – 630
2023
Q3 		$5 Hold
1
– – ﹤0.01% 800
2023
Q2 		$4 Buy
+1
New +$2 ﹤0.01% 499

Other funds holding AMRX

FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Macroview Investment Management's AMRX Position: Q4 2023 in Review

Macroview Investment Management sold out of Amneal Pharmaceuticals (AMRX) in Q4 2023, closing a stake of 1 share — an estimated $5 sold.

Macroview Investment Management first reported a position in AMRX in Q2 2023 and held it in 2 quarters. The position peaked at $5 in Q3 2023. 153 funds tracked by Wall St. Rank hold AMRX as of Q4 2023.

  • Macroview Investment Management reported no remaining Amneal Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Macroview Investment Management sold 1 Amneal Pharmaceuticals share in Q4 2023, an estimated $5.
  • Macroview Investment Management first reported a position in Amneal Pharmaceuticals in Q2 2023 and held it in 2 quarters.
  • Macroview Investment Management's Amneal Pharmaceuticals position peaked at $5 in Q3 2023.
  • 153 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q4 2023.

Based on Macroview Investment Management's 13F filing for Q4 2023, filed 30 Jan 2024.